Johnson & Johnson JNJ

$272.32 -4.00 (-1.45%)

Valuation

Market cap
665,187,904,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
P/E (trailing)
24.99
P/E (forward)
23.94
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
9,661,395
Avg volume
7,182,336
Day's range
$271.64 – $281.92
Shares out
2,407,310,000
Stochastic %K
46%
Beta
0.22
Analysts
Moderate Buy
Price target
$281.64

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

AlertsAndNews Nov 6, 3:31 AM
$JNJ FDA approval Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer "Accelerated approval based on data demonstrating clinically meaningful efficacy, including a 42 percent overall response rate (95 percent confidence interval, 32–52 percent"
0 replies
focafoca99 Nov 6, 2:10 AM
$JNJ approved its dual-targeted RYBREVANT FASPRO for advanced head and neck cancer, the first FDA nod for this therapy. https://www.rapidticker.com/news/jnj-johnson-johnson-announces-us-fda-f0d3ef
0 replies
Rayvio_News_Filter Nov 5, 10:34 PM
$JNJ 🏥 Johnson & Johnson received FDA accelerated approval for Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) to treat adults with recurrent or metastatic head and neck squamous cell carcinoma after platinum-based chemotherapy and immunotherapy, based on trial results showing more than double the response rate versus currently approved therapies. Prioritized by relevance
0 replies
DidYouReadThis Nov 5, 8:51 PM
Does anyone have a #bollinger #bandaid? Where’s $OTLK’s #bottom or #52week #low going to be for 2027? 4 cents? What’s that July 2026 FDA approval worth once 2030 potentially #breaks 500 million? $OTLK $KVUE $JNJ $NVS #eyecare #healthcare #biotech #congrats #missionaccomplished?
0 replies
DrMcSavage Nov 5, 8:33 PM
So healthcare was doing fine but it just got dumped must be some profit taking- still bullish for healthcare $PFE $XLV $JNJ $LLY $MRK
0 replies
BENNYST Nov 5, 3:53 PM
$SLS Market is bleeding, but mother $JNJ doesn’t care—stretching green as always. Hey J&J, time to complete the family and buy us out already! 🟢🚀
0 replies
HydrogenH2 Nov 5, 2:38 PM
$JNJ Taking some profits now !!
0 replies
Adare Nov 5, 11:58 AM
$JNJ pipeline strenght. We should be looking at $400 per share by 2030
0 replies